Introduction
============

Vogt-Koyanagi-Harada (VKH) syndrome is one of the most common uveitis entities in China \[[@r1]\]. The major clinical manifestations of VKH syndrome include panuveitis, pleocytosis in the cerebrospinal fluid, dysacusis, alopecia, poliosis, and vitiligo \[[@r2]-[@r4]\]. Although the pathogenesis of VKH syndrome remains uncertain, accumulating evidence suggests that both autoimmune and genetic factors are involved in the development of this disease. Previous research showed that VKH is a T-cell-mediated autoimmune disorder predominantly against melanocytes \[[@r5]\] and that the tyrosinase family proteins may play an important role in VKH disease. Lymphocytes of VKH patients were shown to proliferate in response to tyrosinase or tyrosinase related protein \[[@r6]\]. VKH occurs most commonly in colored people such as certain Asian, American-Indian, and Spanish populations \[[@r7]\], particularly in those carrying the genes coding for the human leukocyte antigen (*HLA*), *HLA-DR4* and *HLA-DRw53* \[[@r8]-[@r10]\]. A study in our laboratory recently reported that the frequencies of *HLA-DR4* and *HLA-DRw53* were both significantly increased in VKH patients (odds ratios \[OR\]=13.74 and OR=4.13, p=3.21×10^--16^ and p=7.08×10^--5^, respectively) \[[@r11]\]. However, the association between VKH syndrome and the *HLA* system does not completely explain the genetic risk for this disease. Investigation of non-*HLA* susceptibility genes for VKH has been an ongoing research subject during recent years \[[@r12]\].

Fc receptor-like genes (*FCRL*s), also known as *FCRH*s (Fc receptor homology), cluster in the midst of the classical Fc receptor genes in the human chromosome 1q21--23 region \[[@r13]\]. *FCRL*s with similarity in structure and sequence to the classical *Fcγ* receptor genes (*FcγR*) contain six immunoglobulin (Ig) superfamily members known as *FCRL1*--*FCLR6* according to their chromosomal order \[[@r14]\]. *FCRL3* is predominantly expressed in lymphoid organs, more precisely in germinal centers, and has been linked to the maturation of B cells \[[@r15]\]. *FCRL3* may play a role in the differentiation of B cells into autoreactive cells and has been presumed to function through modulating signal transduction via activation/inactivation of signaling tyrosine protein kinases \[[@r16]\]. Recently, polymorphisms of *FCRL3* have been reported to be associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) \[[@r17]\], Behcet's disease \[[@r18]\], autoimmune thyroid disease (AITD) \[[@r17],[@r19]\], and multiple sclerosis (MS) \[[@r20],[@r21]\]. The first two have a strong autoantibody component whereas the latter three are predominately mediated by T-cell response. As an autoimmune disease, VKH may share a common pathogenesis with these autoimmune diseases. Therefore, *FCRL3* was chosen as a target gene for VKH syndrome. Whether SNPs of *FCRL3* are also associated with the susceptibility to VKH syndrome is not yet known, and this question was therefore the subject of the study described here.

Methods
=======

Study participants
------------------

Patients and controls consisted of 230 Chinese VKH patients and 301 healthy controls. All control subjects were matched ethnically and geographically with the patients. The test subjects were recruited from the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) and the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). To exclude the immunogenetic backgrounds of different populations, we strictly chose the cases from Chinese Han descendents.

The diagnosis of VKH syndrome followed the revised criteria for this disease \[[@r22]\]. The clinical characteristics of the patients are presented in [Table 1](#t1){ref-type="table"}. All subjects gave their written informed consent for this study, and the study protocol was approved by the local institutional ethics committee.

###### *HLA-DR4* and *HLA-DRw53* distribution and clinical characteristics of 230 patients with VKH syndrome.

  **Characteristics**      **VKH Patients**                              
  ------------------------ ------------------ ------------ ------------- ------------
  Male                     103 (80.5%)        25 (19.5%)   116 (90.6%)   12 (9.4%)
  Female                   75 (73.5%)         27 (26.5%)   86 (84.3%)    16 (15.7%)
  Neck stiffness           74 (72.5%)         28 (27.5%)   89 (87.3%)    13 (12.7%)
  Alopecia                 26 (72.2%)         10 (27.8%)   30 (83.3%)    6 (16.7%)
  Poliosis                 65 (73.9%)         23 (26.1%)   78 (88.6%)    10 (11.4%)
  Vitiligo                 41 (74.5%)         14 (25.5%)   48 (87.3%)    7 (12.7%)
  Dysacusia                57 (69.5%)         25 (30.5%)   70 (85.4%)    12 (14.6%)
  Tinnitus                 61 (84.7%)         11 (15.3%)   67 (93.1%)    5 (6.9%)
  Scalp hypersensitivity   32 (74.4%)         11 (25.6%)   38 (88.4%)    5 (11.6%)

Single nucleotide polymorphisms and genotyping
----------------------------------------------

Genomic DNA samples of VKH patients and healthy controls were extracted and isolated from ethylene diamine tetraacetic acid (EDTA)-anticoagulated peripheral blood mononuclear cells (PBMCs) by a conventional salting out method and stored at −70 °C until use.

The four single nucleotide polymorphisms (SNPs) in *FCRL3*, −169C/T ([rs7528684](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7528684) or fcrl3_3), −110G/A ([rs11264799](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11264799) or fcrl3_4), +358C/G ([rs945635](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=945635) or fcrl3_5), and +1381A/G ([rs3761959](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761959) or fcrl3_6), were genotyped by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Genotyping of the −110G/A SNP was performed according to the method described previously \[[@r23]\]. The primers of the three remaining loci were designed using premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The details of the primers and enzymes used for PCR-RFLP genotyping are presented in [Table 2](#t2){ref-type="table"}.

###### Details of the primers, enzymes, and temperature used in PCR-RFLP genotyping.

  **SNPs**             **dbSNP ID**                                                            **Forward primer**   **Reverse primer**   **Tm (°C)**   **Restriction enzyme**
  -------------------- ----------------------------------------------------------------------- -------------------- -------------------- ------------- ------------------------
  −169C/T (fcrl3_3)    [rs7528684](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7528684)     GGAAAATAATACA        GGCTTTAAAA           56.9          BsmFI
                                                                                               AATGTACAGATTA        AACGGTGGTAC                        
  −110A/G (fcrl3_4)    [rs11264799](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11264799)   CTCAATCCCGGT         CTCATAACAAC          56.9          PleI
                                                                                               AGTGATACA            TTATGTGAGA                         
  +358C/G (fcrl3_5)    [rs945635](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=945635)       TTATAGCCCATCTA       CCGGGATTGAGA         60.3          HaeIII
                                                                                               CTCACTCAGGATCA       TACAAACAGCATTT                     
  +1381A/G (fcrl3_6)   [rs3761959](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761959)     TCCGACTTTTTCA        TGATAGCAGCACTA       60.3          MspI
                                                                                               GTCTCTAGGTTTT        GCTTGGACATTCA                      

PCR was performed in 15 μl volumes containing 7.5 μl Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co. Ltd., Dalian, China), 0.5 μl primers (10 μmol/l), and 0.1 μg of genomic DNA. The PCR products were then digested by the proper restriction enzymes, separated by electrophoresis on 2%−3% agarose gel, and stained with GoldView™ (SBS Genetech, Beijing, China). The images were recorded digitally. Approximately 20% of the PCR samples were directly sequenced to confirm the PCR-RFLP results (Invitrogen Biotechnology Co., Guangzhou, China). *HLA-DR4* genotyping was performed using the PCR sequence specific primers (SSP) method \[[@r24]\]. *HLA-DRw53* typing was performed as described previously \[[@r25]\].

Statistical analysis
--------------------

Statistical analysis was performed with the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL). The Hardy--Weinberg equilibrium (HWE) was tested by the χ^2^ test. We evaluated the frequency of alleles and genotypes in this study using the χ^2^ test or Fisher's exact test and accounting for multiple testing. The haplotype frequency and linkage disequilibrium (LD) of the SNPs were estimated with the [Haploview](http://www.broad.mit.edu/mpg/haploview/) 3.32 program \[[@r26],[@r27]\]. A haplotype frequency less than 0.03 was not analyzed. All the data were corrected by Bonferroni correction.

Results
=======

The test subjects consisted of 230 VKH patients (aged 33.4±12.6 years) and 301 healthy controls (aged 35.3±11.9 years). Of the 230 patients, 128 (55.7%) were men and 102 (44.3%) were women. No statistical difference was observed between patients and controls in the distribution of age and gender (p=0.43, p=0.82, respectively). All the cases and controls were in Hardy--Weinberg equilibrium (p\>0.05). Therefore, we did the following analysis.

Four SNPs (−169C/T, −110A/G, +358C/G, and +1381A/G) in *FCRL3* were determined in all patients and controls. The results showed that a significantly higher frequency of the G allele at the −110 site of *FCRL3* was observed in VKH patients than in controls (p=0.0129), but this significance was lost after the Bonferroni correction (corrected p \[Pc\]=0.1032; [Table 3](#t3){ref-type="table"}). No significant difference was observed in the distribution of other tested alleles or genotypes between VKH patients and controls. The frequency of haplotype CACG was signficantly lower in VKH patients (0.3%) than in controls(3.0%; p=0.0018,Pc=0.0288, χ^2^=9.77; [Table 4](#t4){ref-type="table"}).

###### Frequency of different alleles and genotypes in four *FCRL3* SNPs in VKH patients and controls.

  **SNPs**       **Patients n=230 (%)**   **Controls n=301 (%)**   **χ^2^**   **p value**    **Pc**   **OR (95% CI)**
  -------------- ------------------------ ------------------------ ---------- -------------- -------- ---------------------
  **−169C/T**                                                                                         
  CC             81 (35.2)                87 (28.9)                4.7365     0.0936         NS       
  CT             82 (35.7)                135 (44.9)               4.7365     0.0936         NS       
  TT             67 (29.1)                79 (26.2)                4.7365     0.0936         NS       
  **Alleles**                                                                                         
  C              244 (53.0)               309 (51.3)               0.3071     0.5794         NS       1.071 (0.840-1.366)
  T              216 (47.0)               293 (48.7)               0.3071     0.5794         NS       
  **−110A/G**                                                                                         
  AA             16 (7.0)                 46 (15.4)                8.738      0.0127         NS       
  AG             81 (35.5)                98 (32.8)                8.738      0.0127         NS       
  GG             131 (57.5)               155 (51.8)               8.738      0.0127         NS       
  **Alleles**                                                                                         
  A              113 (24.8)               190 (31.8)               6.174      0.0129         NS       0.707 (0.538-0.930)
  G              343 (75.2)               408 (68.2)               6.174      0.0129         NS       
  **+358C/G**                                                                                         
  CC             75 (32.6)                100 (33.4)               0.619      [0.734]{.ul}   NS       
  CG             104 (45.2)               141 (47.2)               0.619      [0.734]{.ul}   NS       
  GG             51 (22.2)                58 (19.4)                0.619      [0.734]{.ul}   NS       
  **Alleles**                                                                                         
  C              254 (55.2)               341 (55.7)               0.345      [0.557]{.ul}   NS       0.929 (0.727-1.187)
  G              206(44.8)                257 (43.0)               0.345      [0.557]{.ul}   NS       
  **+1381A/G**                                                                                        
  AA             135 (64.6)               150 (58.6)               8.279      0.016          NS       
  AG             72 (34.4)                91 (35.5)                8.279      0.016          NS       
  GG             2 (1.0)                  15 (5.9)                 8.279      0.016          NS       
  **Alleles**                                                                                         
  A              199 (43.3)               260 (56.5)               1.356      0.5078         NS       ---
  G              256 (42.7)               344 (57.3)               1.356      0.5078         NS       

Pc: Corrected p value; NS: Not significant; OR: odds ratios.

###### Frequencies of *FCRL3* haplotypes in VKH patients and controls.

  **Haplotypes**   **VKH 2n=456 (%)\***   **Controls 2n=594 (%)\***   **χ^2^**   **Fisher's p**   **Pc**   **OR (95% CI)**
  ---------------- ---------------------- --------------------------- ---------- ---------------- -------- -----------------
  C A C G          1.57 (0.3)             17.95 (3.0)                 9.77       0.0018           0.0288   0.1 (0.02-0.59)
  C A G A          78.4 (17.2)            112.0 (18.9)                0.21       0.6454           NS       0.9 (0.67-1.28)
  C G C G          47.5 (10.4)            38.1 (6.4)                  6.34       0.0118           NS       1.8 (1.13-2.76)
  C G G A          91.1 (20.0)            116.9 (19.7)                0.14       0.7137           NS       1.1 (0.78-1.45)
  T A C G          14.7 (3.2)             44.4 (7.5)                  8.12       0.0044           0.0704   0.4 (0.23-0.78)
  T G C G          175.4 (38.5)           219.8 (37.0)                0.81       0.3698           NS       1.1 (0.87-1.46)

The asterisk indicates that the frequency is less than 3% in both VKH cases and control.

We further analyzed the relationship between these SNPs and various extraocular clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo. The detailed clinical findings of the enrolled VKH patients are shown in [Table 1](#t1){ref-type="table"}. No significant difference was noted between any clinical parameter stated above and the investigated SNPs.

*HLA-DR4* and *HLA-DRw53* were also determined in VKH patients and controls using the PCR-SSP and PCR method \[[@r24],[@r25]\]. The results showed that the frequencies of both *HLA-DR4* and *HLA-DRw53* were significantly higher in VKH patients than in healthy controls (77.4% versus 19.6%, p=7.34×10^−16^ and 87.8% versus 64.1%, p=5.59×10^−10^, respectively). Stratification analysis was then performed according to the status of *HLA-DR4* and *HLA-DRw53*. A significant difference was found in the frequency of haplotype CGGG between *HLA-DR4* negative patients and *HLA-DR4* negative controls (5.8% versus 0%, p=9.94×10^−8^, Pc=1.59×10^−6^; [Table 5](#t5){ref-type="table"}). The results did not show any association of allele and genotype frequencies of the four SNPs between VKH patients and normal controls following these stratifications.

###### Frequencies of *FCRL3* haplotypes in *HLA-DR4* negative VKH patients and *HLA-DR4* negative controls.

  **Haplotypes**   **VKH 2n=100 (%)\***   **Controls 2n=478 (%)\***   **χ^2^**   **Fisher's p**   **Pc**      **OR (95% CI)**
  ---------------- ---------------------- --------------------------- ---------- ---------------- ----------- -----------------
  C A C G          2.45 (2.5)             16.79 (3.5)                 0.26       0.6102           NS          0.7 (0.18-0.74)
  C A G A          16.59 (16.6)           86.29 (18.1)                0.074      0.785502         NS          0.9 (0.52-1.65)
  C G C G          6.76 (6.8)             27.20 (5.7)                 0.21       0.646662         NS          1.2 (0.51-2.94)
  C G G A          23.80 (23.8)           94.85 (19.8)                0.987      0.320533         NS          1.3 (0.77-2.19)
  T A C G          2.39 (2.4)             35.27 (7.4)                 3.274      0.070433         NS          0.3 (0.08-1.18)
  T G C G          33.09 (31)             182.16 (38.1)               0.704      0.401591         NS          0.8 (0.51-1.31)
  C G G G          5.78 (5.8)             0.00 (0.000)                28.469     9.94e-08         5.19e-006   

The asterisk indicates that the frequency was less than 3% in both VKH case and control.

Discussion
==========

We analyzed the association of the aforementioned four SNPs and haplotypes of *FCRL3* in the susceptibility to VKH syndrome in a Chinese population. The results showed that the frequency of haplotype CACG was significantly lower in VKH patients and that the frequency of haplotype CGGG was significantly higher in *HLA-DR4* negative VKH patients. The results also confirmed the association of *HLA-DR4* and *HLA-DRw53* with VKH syndrome as expected. Furthermore, previous studies showed strong associations between *FCRL3* polymorphisms and RA in Asian groups but hardly in Caucasians \[[@r16]\] except a study in Spain \[[@r28]\], which showed that *FCRL3* polymorphisms were associated with RA after stratification by nuclear factor kappa B1 (NF-κB1). VKH syndrome is quite common in both Asian and Spanish populations. The association between *FCRL3* and VKH may be of importance in Chinese VKH patients and Hispanic VKH patients.

The test patients were strictly enrolled as VKH syndrome patients according to the revised criteria \[[@r22]\]. As ethnic confounding could influence the results, we selected only Chinese Han descendents as the test subjects. Moreover, the healthy controls in this study were all limited to persons who came from the same places as the patients, which avoided a geographic bias.

As a novel immunoregulatory gene, *FCRL3* has been reported to be positively associated with various autoimmune diseases in different ethnic populations \[[@r17],[@r19],[@r21],[@r29],[@r30]\], though certain results were conflicting \[[@r28],[@r31]\]. A study by Kochi et al. \[[@r17]\] in Japan found that the four SNPs of *FCRL3* (−169C/T, −110A/G, +358C/G, and +1381A/G) were associated with RA and that SNP −169C/T was associated with AITD and SLE. Furthermore, −169C/T SNP has been shown to influence the level of *FCRL3* expression on B cells by altering the binding affinity of NF-κB, which appears to play a major role in the inflammatory response according to recent studies \[[@r32]\]. Therefore, we speculated that polymorphisms within *FCRL3* could also be related to VKH syndrome.

Although no significant differences were found in the frequencies of the four investigated SNPs of *FCRL3* between VKH patients and normal controls, an increase trend was observed in the frequency of the −110G allele in VKH patients. This result is similar to the study we recently reported in Behcet's disease in which only the *FCRL3* −110G allele was significantly higher in BD patients and no differences were observed in the remaining three tested SNPs \[[@r18]\]. The polymorphisms of *FCRL3* were reported to be associated with RA in Japan \[[@r17],[@r30]\] and MS in Spain \[[@r20],[@r21]\], but the associations could not be replicated completely in other autoimmune diseases \[[@r23],[@r33]\]. In the study of Graves' disease \[[@r19]\], three of the four SNPs (except −110A/G SNP) were associated with this autoimmune thyroid disease. A study by Japanese investigators \[[@r34]\] also showed that only −110A/G SNP was associated with autoimmune pancreatitis, but contrary to our result, the frequency of −110G allele was decreased in these patients. Similar negative results were obtained for the same four SNPs of *FCRL3* in other studies concerning type 1 autoimmune hepatitis in the Japanese \[[@r35]\] and SLE in the Chinese population \[[@r36]\]. These observations demonstrated that the relationship between polymorphisms of *FCRL3* and autoimmune diseases is more complex than we thought, especially in some multiple autoimmune disorders.

The further haplotype analysis showed that the frequency of haplotype CACG was significantly lower in VKH patients. This suggests that the haplotype CACG might be a protective haplotype for VKH syndrome. However, the frequency of this haplotype in patients and controls is very low (0.3% versus 3%), making it hard to make any firm conclusion on this significance. The present results were different from those found in BD \[[@r18]\] and SLE \[[@r37]\]. The study of BD in our laboratory found that haplotype CGCG and TACG were both associated with BD in which the first one was found to be significantly higher whereas the latter was significantly lower in BD patients as compared with healthy controls. While in the study of SLE in Spanish individuals, only three alleles were examined and the frequency of haplotype CGA was found to be significantly higher in SLE patients than in controls.

VKH occurs most commonly in pigmented individuals and not in whites, but interestingly, the disease is rare in Africans \[[@r7]\]. It seems that the genetic background in these individuals rather than the amount of pigment is the predisposing factor to VKH syndrome. Various studies have reported that *HLA-DR4* and *HLA-DRw53* were significantly associated with VKH syndrome \[[@r8]-[@r10]\]. We therefore analyzed the association of the four SNPs with VKH syndrome based on the *HLA-DR4* and *HLA- DRw53* stratification. We found that the association of *HLA-DR4* and *HLA-DRw53* with VKH syndrome was extremely strong, which is consistent with earlier studies from China \[[@r8],[@r38]\], Japan \[[@r10]\], Korea \[[@r39]\], and Hispanic patients living in California \[[@r40]\]. However, stratification analysis according to the status of *HLA-DR4* and *HLA-DRw53* still showed that none of the four SNPs was associated to VKH syndrome. However, the frequency of haplotype CGGG was significantly higher in *HLA-DR4* negative patients than in *HLA-DR4* negative controls. Haplotype CGGG is probably a risk haplotype predisposing to VKH syndrome in *HLA-DR4* negative subgroups. The samples become small after stratification, consisting of 52 *HLA-DR4* negative VKH patients and 242 *HLA-DR4* negative normal controls. The influence of insufficient sample size can not be excluded yet. Various studies showed that VKH shared epitopes with other autoimmune disease-associated HLA alleles \[[@r41]-[@r43]\]. *HLA-DQB1*, -*DR1*, and -*DR4* all were susceptible genes for VKH syndrome \[[@r44]\], and importantly, these HLA antigens were also associated with the susceptibility to other autoimmune diseases including type 1 diabetes \[[@r45]\]and Graves\' disease \[[@r46]\].

Systemic disease is a prominent feature of VKH syndrome. There is a large variation in systemic clinical manifestations in Chinese VKH patients \[[@r4]\]. Stratification analysis was therefore performed to investigate the association between the polymorphisms of *FCRL3* and clinical manifestations. The results showed that none of these clinical findings, which included neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo, was significantly associated with the four SNPs. Similarly, no association was found after gender and age stratification.

In conclusion, no significant correlation could be observed between the *FCRL3* polymorphisms and VKH syndrome in the Chinese population. Haplotype CACG might be a protective haplotype for VKH syndrome. Haplotype CGGG is probably a risk haplotype in *HLA-DR4* negative individuals. Similar to previous studies, we found strong associations of *HLA-DR4* and *HLA-DRw53* with VKH syndrome. Further studies of these SNPs and including other variants in the *FCRL3* region, using larger (multi-center) patient numbers, and including various autoimmune diseases should be performed in the future.
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